Different kinetics for the hepatic uptake of lipid nanoparticles between the apolipoprotein E/low density lipoprotein receptor and the N-acetyl-d-galactosamine/asialoglycoprotein receptor pathway
- PMID: 32145269
- DOI: 10.1016/j.jconrel.2020.03.006
Different kinetics for the hepatic uptake of lipid nanoparticles between the apolipoprotein E/low density lipoprotein receptor and the N-acetyl-d-galactosamine/asialoglycoprotein receptor pathway
Abstract
Lipid nanoparticles (LNPs) are one of the more promising technologies for efficiently delivering nucleic acids in vivo. Hepatocytes are the primary target cells of LNPs that are delivered via the apolipoprotein E (ApoE)-low density lipoprotein receptor (LDLR) pathway, an endogenous targeting pathway. This robust targeting mechanism results in the specific and efficient delivery of nucleic acids to hepatocytes. Trivalent N-acetyl-D-galactosamine (GalNAc) is known to be a high-affinity exogenous ligand against the asialoglycoprotein receptor (ASGPR), which is highly expressed on hepatocytes. In this study, we report that the kinetics of the hepatic uptake process between the two types of targeting pathways are different. Rapid blood clearance, accumulation to the space of Disse and a subsequent slow cellular uptake was observed in the case of the endogenous ApoE-LDLR pathway. On the other hand, both blood clearance and cellular uptake were more gradual in the case of the exogenous GalNAc-ASGPR pathway. Interactions between ApoE-bound LNPs and hepatic heparan sulfate proteoglycans (HSPGs) were involved in the rapid blood clearance and accumulation to the space of Disse in the case of the endogenous pathway. The findings presented here contribute to a more precise understanding of the mechanism of hepatic uptake and to the rational design of hepatocyte-targeting nanoparticles.
Keywords: Apolipoprotein E; Asialoglycoprotein receptor; Heparansulfate proteoglycan; Hepatic uptake; Lipid nanoparticles; Low density lipoprotein receptor; N-acetyl-D-galactosamine.
Copyright © 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors who have taken part in this study declare that they have nothing to disclose regarding funding or conflicts of interest with respect to this manuscript.
Similar articles
-
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.Mol Ther. 2010 Jul;18(7):1357-64. doi: 10.1038/mt.2010.85. Epub 2010 May 11. Mol Ther. 2010. PMID: 20461061 Free PMC article.
-
Advancement of drugs conjugated with GalNAc in the targeted delivery to hepatocytes based on asialoglycoprotein receptor.Carbohydr Res. 2025 Jun;552:109426. doi: 10.1016/j.carres.2025.109426. Epub 2025 Feb 27. Carbohydr Res. 2025. PMID: 40068307 Review.
-
Effect of gal/GalNAc regioisomerism in galactosylated liposomes on asialoglycoprotein receptor-mediated hepatocyte-selective targeting in vivo.J Liposome Res. 2021 Mar;31(1):79-89. doi: 10.1080/08982104.2019.1682606. Epub 2019 Nov 6. J Liposome Res. 2021. PMID: 31691619
-
Serial incorporation of a monovalent GalNAc phosphoramidite unit into hepatocyte-targeting antisense oligonucleotides.Bioorg Med Chem. 2016 Jan 1;24(1):26-32. doi: 10.1016/j.bmc.2015.11.036. Epub 2015 Nov 27. Bioorg Med Chem. 2016. PMID: 26678173
-
Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications.J Control Release. 2015 Apr 10;203:126-39. doi: 10.1016/j.jconrel.2015.02.022. Epub 2015 Feb 18. J Control Release. 2015. PMID: 25701309 Review.
Cited by
-
Impact of Lipid Tail Length on the Organ Selectivity of mRNA-Lipid Nanoparticles.Nano Lett. 2024 Oct 7;24(41):12758-67. doi: 10.1021/acs.nanolett.4c02566. Online ahead of print. Nano Lett. 2024. PMID: 39373269 Free PMC article.
-
Fluorine-modified polymers reduce the adsorption of immune-reactive proteins to PEGylated gold nanoparticles.Nanomedicine (Lond). 2024;19(11):995-1012. doi: 10.2217/nnm-2023-0357. Epub 2024 Apr 9. Nanomedicine (Lond). 2024. PMID: 38593053 Free PMC article.
-
Drug Targeting and Nanomedicine: Lessons Learned from Liver Targeting and Opportunities for Drug Innovation.Pharmaceutics. 2022 Jan 17;14(1):217. doi: 10.3390/pharmaceutics14010217. Pharmaceutics. 2022. PMID: 35057111 Free PMC article. Review.
-
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases.Acta Biomater. 2021 Sep 1;131:16-40. doi: 10.1016/j.actbio.2021.06.023. Epub 2021 Jun 18. Acta Biomater. 2021. PMID: 34153512 Free PMC article. Review.
-
Isolation of recombinant apolipoprotein E4 N-terminal domain by foam fractionation.Protein Expr Purif. 2023 Oct;210:106319. doi: 10.1016/j.pep.2023.106319. Epub 2023 Jun 6. Protein Expr Purif. 2023. PMID: 37290717 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous